Additional Advances in Esophagogastric Cancer Research and Clinical Trials

Complete the full activity here: https://bit.ly/45606Oq Watch Module 1: https://www.youtube.com/watch?v=LmTWPr7GSc0&t=2s Watch Module 2: https://www.youtube.com/watch?v=3zWERGHtUu8 Watch Module 3: https://www.youtube.com/watch?v=g5ABcgmRS8o Watch the full interview on Oncology Data Advisor: https://oncdata.com The treatment of esophagogastric cancer has undergone a profound transformation, moving away from the "nihilism" of the early 2000s toward a redefined strategy of immune priming and molecular precision. In this edition of Additional Advances, Yelena Janjigian, MD, Chief of the GI Oncology Service at Memorial Sloan Kettering Cancer Center, discusses the latest clinical breakthroughs and the critical importance of multidisciplinary care. Dr. Janjigian explores the paradigm shift toward perioperative chemoimmunotherapy, highlighting how initiating treatment before surgery can "educate" the immune system and lead to pathologic complete responses with near-100% cure rates. She addresses the dangers of clinical understaging and explains why a "belt and suspenders" approach—incorporating PET, CT, laparoscopy, and cytology—is essential for accurate treatment planning. The conversation also emphasizes the non-negotiable need for universal biomarker testing (MSI, PD-L1, HER2, and CLDN18.2) for all adenocarcinoma patients and the vital role of medical oncology input before any surgical intervention. With landmark data emerging from trials like MATTERHORN and CheckMate 649, Dr. Janjigian shares a message of significant optimism for achieving long-term survival in esophagogastric cancer. Follow us here: Facebook https://www.facebook.com/i3Health Instagram https://www.instagram.com/i3health Soundcloud https://soundcloud.com/i3-health X https://twitter.com/i3health